In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Patrick Kelly, Chief Advocacy Officer at the Healthcare Distribution Alliance, to discuss why generic markets face razor-thin margins and concentration risk, what is driving recent drug shortages, how tariffs and reshoring could affect costs, potential ripple effects from Most Favored Nation pricing, and the rise of direct-to-consumer pathways and traceability across the supply chain.

Key Topics:


Generic Market Pressures: Race-to-the-bottom pricing, manufacturer exits, concentration risks.


Shortage Drivers: Telemedicine demand spikes for controlled substances, facility shutdowns, and sterile injectable constraints.


Tariffs and Reshoring: Section 232 outlook, potential India duties, pass-through pressures to patients.


MFN Pricing Impacts: Inventory devaluation risk, price-depreciation clauses, manufacturer responses.


DTC and Traceability: Direct-to-consumer models, pharmacy and provider roles, DSCSA unit-level safety.

Opinions expressed are those of the speakers.

In this episode of the Vital Health Podcast, host <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/">Duane Schulthess</a> speaks with <a href="https://www.linkedin.com/in/patrick-kelly-08427a8">Patrick Kelly</a>, Chief Advocacy Officer at the <a href="https://www.linkedin.com/company/hdma">Healthcare Distribution Alliance</a>, to discuss why generic markets face razor-thin margins and concentration risk, what is driving recent drug shortages, how tariffs and reshoring could affect costs, potential ripple effects from Most Favored Nation pricing, and the rise of direct-to-consumer pathways and traceability across the supply chain.
Key Topics:
<ul data-start="535" data-end="1091">
<li data-start="535" data-end="635">
Generic Market Pressures: Race-to-the-bottom pricing, manufacturer exits, concentration risks.
</li>
<li data-start="636" data-end="765">
Shortage Drivers: Telemedicine demand spikes for controlled substances, facility shutdowns, and sterile injectable constraints.
</li>
<li data-start="766" data-end="875">
Tariffs and Reshoring: Section 232 outlook, potential India duties, pass-through pressures to patients.
</li>
<li data-start="876" data-end="982">
MFN Pricing Impacts: Inventory devaluation risk, price-depreciation clauses, manufacturer responses.
</li>
<li data-start="983" data-end="1091">
DTC and Traceability: Direct-to-consumer models, pharmacy and provider roles, DSCSA unit-level safety.
</li>
</ul>
Opinions expressed are those of the speakers.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess, Managing Director of Vital Tran…